Study Information

Title: A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer External
Status: Recruiting participants
Conditions: Systemic Anaplastic Large-Cell Lymphoma; Neoplasms; Anaplastic Lymphoma Kinase, Human; NSCLC
Interventions: Drug: PF-02341066; Drug: Rifampin; Drug: Ketoconazole
Health Topics: Adenocarcinoma of the Lung, Lung Cancer Overview, Non-Hodgkin Lymphoma, Squamous cell carcinoma of the lung

Contact Information

Pfizer Investigational Site
Boston, MA 02114
Pfizer Investigational Site
Boston, MA 02115